DisclosureWe earn commission on partner links; ranking is set by clinician-vetted methodology — not advertisers.
April 2026 Nature study identified GLP1R + GIPR variants that predict weight-loss response + nausea risk. Free predictor based on your 23andMe data — explains 15-25% of response variance.
First DTC pharmacogenomics tool for GLP-1
23andMe Research Institute April 2026 Nature paper identified 4 high-impact variants in GLP1R, GIPR, and downstream signaling genes. Free predictor based on those findings. Genetics explain only 15-25% of response variance — useful for expectations, not deterministic.
Your genetic variants
If you have 23andMe data, look up each rsID in your raw data. Mark "favorable" for protective allele, "unfavorable" for risk allele, "unknown" if not tested. See variant details below for which alleles are favorable.
rs10305420
GLP1R · Pro7Leu missense variant in GLP-1 receptor
Effect: Pro7Leu missense variant in GLP-1 receptor — alters receptor sensitivity
Population frequency: T (minor) ~30% in European, ~5% in African ancestry populations
Weight loss: TT genotype carriers showed ~20% greater weight loss on semaglutide vs CC carriers in 23andMe Apr 2026 study.
Nausea: No clear effect on nausea/GI side effects.
rs6923761
GLP1R · Gly168Ser variant
Effect: Gly168Ser variant — affects signaling downstream of receptor
Population frequency: A (minor) ~40% across populations
Weight loss: AA carriers show ~12% greater weight loss on semaglutide. Effect attenuated for tirzepatide (dual mechanism).
rs1042044
GIPR · Lys46Glu missense in GIP receptor
Effect: Lys46Glu missense in GIP receptor — alters tirzepatide-specific signaling
Population frequency: G (minor) ~25% European, ~50% Asian populations
Weight loss: GG genotype carriers show enhanced response to tirzepatide (Mounjaro/Zepbound/Foundayo). Less impact on semaglutide.
rs5443
GNB3 · C825T variant
Effect: C825T variant — affects G-protein signaling cascade
Population frequency: T (minor) ~30% European, ~60% Asian
Weight loss: No strong direct weight-loss effect.
Nausea: TT genotype carriers report 2x more severe nausea on GLP-1 therapy. Consider slower titration.
23andMe Total Health includes GLP-1 response report (based on April 2026 Nature study). Nucleus provides similar coverage with broader genome scope.
Predictive, not diagnostic. Genetic predictors explain 15-25% of inter-individual GLP-1 response variance. The other 75-85% is environment + adherence + comorbidity. Don\'t avoid treatment based on this alone. Discuss with prescriber.
15-25% of inter-individual variance in weight loss is explained by GLP1R + GIPR variants per April 2026 Nature study. The other 75-85% is environment, adherence, lifestyle, comorbidities, and dose escalation. Genetics inform but don't determine outcome.
No. Even low-responders typically lose 8-12% body weight at 68 weeks — still clinically significant. The profile tells you what to expect, not whether to treat. Discuss with prescriber about dose escalation strategy.
23andMe Total Health ($199 + $99/yr) is most accessible — explicit GLP-1 response report based on the April 2026 Nature study. Nucleus ($300, one-time) does whole genome and gives broader pharmacogenomic context. For most users, 23andMe is enough.
Rarely. Most pharmacogenomic testing for GLP-1 is currently considered investigational by insurance. 23andMe + Nucleus are self-pay. Some integrative medicine + obesity specialty clinics include in their service packages.
Not directly. Genetics inform drug selection (semaglutide vs tirzepatide, expected dose) but don't replace BMI/comorbidity criteria for insurance approval. Use this to guide conversation with your prescriber, not bypass the standard pathway.
Useful — variants are inherited. If a sibling tried GLP-1 with poor response, your shared variants suggest you may have similar experience. Conversely, "super-responder" family members suggest you may benefit. Not deterministic but informative.
Educational tool, not diagnostic. Pharmacogenomic predictors are probabilistic — your individual response may vary. Don\'t avoid treatment based on this alone. Always discuss with your prescriber. Affiliate disclosure: we link to 23andMe + Nucleus and may earn commission.